Abivax SA
ABVX105.270USD
+1.370+1.32%
Cierre 11/07, 16:00（ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de Abivax SA Compañía
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Información de Abivax SA
Símbolo de cotizaciónABVX
Nombre de la empresaAbivax SA
Fecha de salida a bolsaJun 26, 2015
Director ejecutivoMr. Marc De Garidel
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscal- -
Dirección7-11 Boulevard Haussmann
CiudadPARIS
Bolsa de valoresEuronext Paris
PaísFrance
Código postal75009
Teléfono33153830963
Sitio Webhttps://www.abivax.com/
Símbolo de cotizaciónABVX
Fecha de salida a bolsaJun 26, 2015
Director ejecutivoMr. Marc De Garidel
Ejecutivos de Abivax SA
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
,
,
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Kevin Shan
Kevin Shan
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Ms. Sophie Lacourrege
Ms. Sophie Lacourrege
Vice President, HR Business Partner, Engagement and Culture
Vice President, HR Business Partner, Engagement and Culture
--
--
Nadege Briancon-eris
Nadege Briancon-eris
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Jennifer Fine
Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Douglas Jacobstein
Douglas Jacobstein
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mary Mantock
Mary Mantock
Senior Vice President, Global Head - Regulatory Affairs
Senior Vice President, Global Head - Regulatory Affairs
--
--
Mr. Patrick Malloy
Mr. Patrick Malloy
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
,
,
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Kevin Shan
Kevin Shan
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Ms. Sophie Lacourrege
Ms. Sophie Lacourrege
Vice President, HR Business Partner, Engagement and Culture
Vice President, HR Business Partner, Engagement and Culture
--
--
Nadege Briancon-eris
Nadege Briancon-eris
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Jennifer Fine
Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Douglas Jacobstein
Douglas Jacobstein
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 8 de nov
Actualizado: sáb., 8 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.73%
Adar1 Capital Management LLC
4.17%
Cormorant Asset Management, LP
2.90%
Caligan Partners, LP
2.28%
Otro
77.69%
Accionistas
Accionistas
Proporción
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.73%
Adar1 Capital Management LLC
4.17%
Cormorant Asset Management, LP
2.90%
Caligan Partners, LP
2.28%
Otro
77.69%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
24.85%
Investment Advisor
12.52%
Investment Advisor/Hedge Fund
6.12%
Venture Capital
1.86%
Research Firm
0.89%
Otro
53.77%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
120
34.39M
46.74%
-4.46M
2025Q2
74
31.84M
43.27%
-317.11K
2025Q1
74
31.82M
50.18%
-39.44K
2024Q4
67
29.91M
47.53%
+1.67M
2024Q3
53
27.43M
43.59%
-1.47M
2024Q2
50
28.12M
44.69%
-980.96K
2024Q1
45
23.37M
37.15%
+1.78M
2023Q4
32
21.64M
34.39%
+20.54M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
TCG Crossover Management, LLC
6.06M
8.23%
--
--
Jun 30, 2025
Deep Track Capital LP
3.48M
4.73%
-99.06K
-2.77%
Jun 30, 2025
Adar1 Capital Management LLC
3.07M
4.17%
+861.32K
+38.97%
Jun 30, 2025
Cormorant Asset Management, LP
2.13M
2.9%
--
--
Jun 30, 2025
Caligan Partners, LP
1.67M
2.28%
+405.28K
+31.93%
Jun 30, 2025
Nantahala Capital Management, LLC
1.48M
2.02%
--
--
Jun 30, 2025
Franklin Advisers, Inc.
1.37M
1.86%
--
--
Jun 30, 2025
VR Adviser, LLC
1.35M
1.83%
--
--
Jun 30, 2025
Great Point Partners, LLC
1.29M
1.76%
-346.49K
-21.15%
Jun 30, 2025
Octagon Capital Advisors LP
1.27M
1.72%
+37.00K
+3.01%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
Simplify Health Care ETF
4.12%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
0%
Innovator IBD Breakout Opportunities ETF
0%
Simplify Health Care ETF
Proporción4.12%
Fidelity Nasdaq Composite Index ETF
Proporción0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporción0%
Innovator IBD Breakout Opportunities ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
